Tarsus Pharmaceuticals Inc (TARS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) has a cash flow conversion efficiency ratio of 0.193x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($66.77 Million) by net assets ($346.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TARS stock market capitalisation for the company's overall valuation and market capitalisation.
Tarsus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Tarsus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tarsus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tarsus Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore TARS cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GZ Port
SHG:601228
|
0.010x |
|
Legend Biotech Corp
NASDAQ:LEGN
|
-0.017x |
|
Life360, Inc. Common Stock
NASDAQ:LIF
|
0.032x |
|
BBVA Banco Frances SA
BA:BBAR
|
0.203x |
|
Viohalco S.A
BR:VIO
|
0.050x |
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
-0.067x |
|
Grupa KĘTY SA
WAR:KTY
|
0.077x |
|
Inter Cars S.A.
WAR:CAR
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Tarsus Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Tarsus Pharmaceuticals Inc from 2018 to 2025. View Tarsus Pharmaceuticals Inc (TARS) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $343.43 Million | $-12.45 Million | -0.036x | +90.20% |
| 2024-12-31 | $224.53 Million | $-83.03 Million | -0.370x | +38.00% |
| 2023-12-31 | $196.99 Million | $-117.49 Million | -0.596x | -134.66% |
| 2022-12-31 | $192.90 Million | $-49.03 Million | -0.254x | -1230.69% |
| 2021-12-31 | $166.73 Million | $3.75 Million | 0.022x | +117.65% |
| 2020-12-31 | $165.98 Million | $-21.14 Million | -0.127x | -120.82% |
| 2019-12-31 | $-6.00 Million | $-3.67 Million | 0.612x | -29.99% |
| 2018-12-31 | $-1.35 Million | $-1.18 Million | 0.874x | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more